Sanofi - Worsens Q3 prelim estimate of currency impact on business EPS -9.5% to -8.5% (prior -7.5% to -6.5%)
- Sees Q3 prelim estimate of currency impact on sales -8.5% to -7.5%
- Sees H2 capital gains from product divestments at €200M
- Guides FY23 gross margin 'improvement'
- Sees FY23 capital gains from product divestments at ~€600M